

Table of Contents

About the Author	v
Table of Chapters	vii
Table of Contents	ix

Chapter 1 Introduction to the Deal Lawyer’s COVID-19 Initiatives

I. INTRODUCTION TO THIS BOOK.....	1-2
A. Relationship Between This Book and the Mergers, Acquisitions and Tender Offers Treatise	1-2
B. A Deal Lawyer’s Approach.....	1-2
C. The Congressional Legislative Responses to the COVID-19 Crisis.....	1-2
D. Introduction to the Chapters.....	1-3
II. REFERENCES	1-5
III. WHAT IS NOT COVERED IN THIS BOOK	1-5

Chapter 2 Congress’s Fiscal Policy COVID-19 Initiatives: The PPP and Treasury Financial Assistance

I. SCOPE	2-4
II. A DEAL LAWYER’S “HOP, SKIP, AND JUMP” THROUGH THE CARES ACT.....	2-5
A. Introduction to the Provisions of the CARES Act	2-5
B. Brief Introduction to Title I, Keeping American Workers Paid and Employed.....	2-5
C. Title II, Assistance for American Workers, Families, and Businesses.....	2-6
D. Title III, Supporting America’s Health Care System in the Fight Against the Coronavirus	2-6
E. Title IV, Economic Stabilization and Assistance to Severely Distressed Sectors of the United States Economy	2-6
F. Conclusion of the “Hop, Skip, and Jump”.....	2-7
III. INTRODUCTION TO THE PAYCHECK PROTECTION PROGRAM (PPP) AND THE RELATED LOAN FORGIVENESS PROGRAM	2-7
A. In General	2-7
B. The Hypothetical Facts That Are Periodically Referred to in Sections II.C (PPP Loans) and II.D (Loan Forgiveness)	2-8

C.	Issues Related to the Making of the PPP Loan	2-9
1.	Introduction.....	2-9
2.	What Are Some of the Key Definitions Under Section 7(a)(36) As Enacted by Section 1102 of the CARES Act?.....	2-9
3.	What Companies Qualify As “Eligible Recipients” of a PPP Loan and Is SCC an Eligible Recipient?	2-10
4.	Does the SBA Guarantee the Loan?.....	2-10
5.	What Institutions Actually Make the PPP Loan?	2-11
6.	Is There Special Funding for Banks and Other Financial Institutions That Make PPP Loans?.....	2-11
7.	What Underwriting Standards Apply to a Lender?	2-11
8.	How Much Is Allocated to PPP Loans?.....	2-11
9.	Are “Real” Small Companies Disadvantaged by the PPP’s “First-Come, First-Served” Policy?	2-12
10.	What Is the Maximum Loan Amount?	2-13
11.	What Are the Allowable Uses of a PPP Loan?	2-13
12.	What Certifications Is the Borrower Required to Give?.....	2-14
13.	What Is the Maturity Period of a PPP Loan?	2-14
14.	What Is the Interest Rate on the PPP Loan?	2-15
15.	When Will the Borrower Have to Begin Making Interest and Principal Payments?	2-15
16.	Can PPP Loans Be Sold in the Secondary Market?.....	2-15
17.	What Fees Does the Borrower Have to Pay, Is the Borrower Required to Seek Other Financing, Is a Personal Guarantee Required, and Is There a Prepayment Penalty?.....	2-16
18.	Is the Loan Recourse?.....	2-16
19.	How Are PPP Loans Treated from the Perspective of the Lender’s Regulatory Requirements?	2-16
20.	How Do the Banks and Other Loan Processors Get Paid?	2-16
21.	What Fees Can an Agent of the Borrower Collect?.....	2-16
D.	Issues Related to the Forgiveness (Loan Forgiveness) of All or Part of the PPP Loan	2-18
1.	Introduction to the Loan Forgiveness Provision	2-18
2.	What Are Some of the Key Definitions Under Section 1106 and How Do They Relate to the Hypothetical Facts in Section III.B?.....	2-18
3.	The Basic Loan Forgiveness Rule.....	2-19
a.	The Starting Principle	2-19
b.	Comparing the Maximum Amount of Loan Forgiveness with the Maximum Loan Amount in Section 7(a)(36)(E).....	2-20
c.	Application to the Hypothetical Facts	2-20

Table of Contents

4.	Limitations on the Basic Loan Forgiveness Rule.....	2-21
a.	Introduction	2-21
b.	The Limitation in the SBA Interim Final PPP Rule: The 25% Limitation	2-21
i.	The Rule.....	2-21
ii.	Application to the Hypothetical Facts	2-22
c.	Forgiveness Limited to the Amount of Financing	2-22
d.	Reduction in Loan Forgiveness Based on Reduction in Number of Employees.....	2-22
e.	Reduction in Loan Forgiveness Based on Reduction in Compensation.....	2-22
f.	Special Rule for Rehires	2-23
g.	Application of the Reduction Rule to the Hypothetical Facts	2-23
5.	Treatment of the Amounts Forgiven.....	2-23
a.	Introduction	2-23
b.	General and Tax Treatment of Forgiven Amounts	2-23
c.	Payment to the Lender of the Forgiven Amount	2-23
d.	Basic Illustration of the Flow of Funds in a PPP Loan That Is Forgiven	2-24
e.	Advance Purchase of the Forgiven Amount.....	2-24
6.	Procedural Requirements for Request by an Eligible Recipient for Loan Forgiveness.....	2-24
7.	The Paycheck Protection Program Flexibility Act of 2020	2-25
IV.	INTRODUCTION TO TREASURY’S AUTHORITY TO MAKE LOANS, LOAN GUARANTEES, AND OTHER INVESTMENTS (THAT IS, TREASURY FINANCIAL ASSISTANCE), SECTIONS 4003 AND 4004	2-25
A.	Introduction.....	2-25
B.	Definition of Eligible Business, Air Carriers and Certain Other Needy Businesses, Section 4002(4).....	2-26
C.	Amount of Treasury Financial Assistance, Section 4003(B), the Four Funding Facilities	2-26
D.	Terms and Conditions for Treasury Financial Assistance for Airline, Air Cargo, and National Security Firms Relief Facilities	2-27
1.	The Section 4003(c)(2) Terms and Conditions	2-27
2.	Generally Applicable Terms and Conditions.....	2-28
3.	The Section 4004 Compensation Condition for All Four Facilities.....	2-28
a.	The Compensation Limitation	2-28
b.	The Practical Effect of the Compensation Limitation	2-29

4.	Financial Protection of Government, Section 4003(d): For Treasury Airline, Air Cargo, and National Security Firms Relief Facilities	2-29
E.	Terms and Conditions for Treasury Financial Assistance Under Section 4004(b)(4) for Fed Programs	2-30
1.	Introduction.....	2-30
2.	Fed Financial Assistance That Is a Direct Loan.....	2-30
3.	Applicability of Section 13(3) of the Federal Reserve Act.....	2-31
4.	Domestic Entity Requirement	2-31
F.	Treasury Assistance to Banks Serving Mid-Sized Businesses, Section 4003(c)(3)(D)(i).....	2-32
G.	The Fed's Main Street Lending Program, Section 4003(c)(3)(D)(ii)	2-33
H.	Loans Treated As Debt for Federal Income Tax Purposes, Section 4003(h).....	2-33
I.	Federal Reserve Board and Banking Provisions of the CARES Act.....	2-33
V.	LENDER FORBEARANCE ON CERTAIN MORTGAGE LOANS AND MORATORIUM ON EVICTIONS.....	2-34
VI.	CONCLUSION	2-34

Chapter 3 Federal Reserve Board's Monetary Policy and Bank Regulatory COVID-19 Initiatives

I.	SCOPE	3-3
II.	BRIEF INTRODUCTION TO THE FED'S "CONVENTIONAL MONETARY POLICY TOOLS"	3-3
A.	In General	3-3
B.	Open Market Operations	3-4
C.	The Discount Rate	3-4
D.	The Reserve Requirement	3-5
III.	BRIEF INTRODUCTION TO THE FED'S NON-CONVENTIONAL MONETARY POLICY TOOLS EMPLOYED IN THE 2007-2008 FINANCIAL CRISIS, QUANTITATIVE EASING (QE)	3-5
IV.	AUTHORITY FOR THE FED TO UTILIZE NON-CONVENTIONAL MONETARY TOOLS, SECTION 13(3) OF THE FEDERAL RESERVE ACT.....	3-6
V.	THE FED'S MONETARY POLICY STANCE IMMEDIATELY PRIOR TO AND DURING THE COVID-19 CRISIS.....	3-7
A.	The January 29, 2020, Fed Meeting: The Tune Keeps on Humming: Steady As the Economy Goes	3-7
B.	The March 3, 2020, Fed Meeting: The Tune Changes Slightly with a Moderate Conventional Monetary Policy Response	3-7

Table of Contents

C.	The March 15, 2020, Fed Meeting: The Tune Changes Radically with an Aggressive Conventional Monetary Policy Response	3-8
D.	March 23, 2020, Fed Meeting, Fed Announces Extensive New Non-Conventional Monetary Measures to Support the Economy	3-8
E.	March 27, 2020, Congress Enacts the CARES Act	3-10
F.	The April 9, 2020, Fed Follow-Up to the Fed’s March 23, 2020 Announcement.....	3-10
	1. The Updated Programs, Including the PMCCF, SMCCF, and TALF.....	3-10
	2. The Main Street Lending Program.....	3-11
	3. More on Main Street and the Primary and Secondary Market Corporate Credit Facilities (PMCCF)	3-11
	4. Programs Issued Under Section 13(3) of the Federal Reserve Act.....	3-11
VI.	INTRODUCTION TO TREASURY’S AUTHORITY TO MAKE LOANS, LOAN GUARANTEES, AND OTHER INVESTMENTS (THAT IS, TREASURY FINANCIAL ASSISTANCE) BOTH DIRECTLY AND THROUGH THE FED, SECTIONS 4003 AND 4004 OF THE CARES ACT	3-12
	A. In General	3-12
	B. The Four Treasury Financial Assistance Programs.....	3-12
	C. The Three Direct Treasury Financial Assistance Programs.....	3-13
	D. The Treasury Financial Assistance for the Fed and Leveraging by the Fed	3-13
	1. In General.....	3-13
	2. Is It Treasury’s Equity Contribution to the Fed a Mirage?	3-14
	E. While It Is a Lot of Money, All of It Is Invested in the Form of Loans or Otherwise.....	3-14
VII.	INTRODUCTION TO BASIC RULES GOVERNING FED FINANCIAL ASSISTANCE, AS ENACTED BY THE CARES ACT	3-14
	A. In General	3-14
	B. Section 4003(c)(3), Restrictions on Dividends, Buybacks and Compensation	3-14
	C. Applicability of Section 13(3) Principles.....	3-15
	D. Only U.S. Businesses to Benefit.....	3-15
	E. Assistance to Mid-Sized Businesses, That Is, Between 500 and 20,000 Employees	3-15
	1. General Rule	3-15
	2. Limitations on Interest Rate and Repayment of Principal	3-16
	3. Required Certifications	3-16
	4. Special Rules for Main Street Lending Program.....	3-17
	F. Support of Lending to Governments	3-17
VIII.	OTHER PROVISIONS OF TITLE IV OF THE CARES ACT APPLICABLE TO BANKING GENERALLY	3-17

IX.	ADDITIONAL INFORMATION ON THE FED'S MAIN STREET PROGRAMS	3-18
X.	ADDITIONAL INFORMATION ON THE FED'S PRIMARY MARKET CORPORATE CREDIT FACILITY (PMCCF)	3-20
XI.	CONCLUSION	3-20

Chapter 4 Corporate, Securities, and Stock Exchange COVID-19 Initiatives

I.	SCOPE	4-2
II.	A REMINDER: CARES ACT CORPORATE GOVERNANCE PROVISIONS	4-3
III.	AN INTRODUCTION TO FIDUCIARY DUTY ISSUES FACED BY DIRECTORS IN VIEW OF COVID-19	4-3
	A. Background	4-3
	B. The Bedrock Principles of the Duty of Care, the Duty of Loyalty, the Business Judgment Rule, and Director Exculpation	4-3
	C. Fiduciary Duties of Directors When the Company Is in the Zone of Insolvency	4-4
	D. Possible Formation of a Special Committee of the Board to Oversee the Response to COVID-19	4-5
IV.	RESPONSES TO A HOSTILE OFFER: THE <i>UNOCAL</i> STANDARD OF REVIEW, AND THE POISON PILL DEFENSIVE MEASURE	4-6
	A. Introduction	4-6
	B. Fiduciary Duties in Responding to a Hostile Bid; the Basic Principle: <i>Unocal</i>	4-7
	C. The Resurgent Poison Pill	4-8
	D. The NOL Pill	4-10
V.	STATE LAW AND SECURITIES LAW GOVERNING SHAREHOLDER MEETINGS IN RESPONSE TO COVID-19	4-12
	A. Introduction	4-12
	B. The Delaware Stockholder Meeting Requirement	4-13
	C. The New York In-Person Shareholder Voting Requirement Suspended	4-13
	D. SEC Initiatives on Virtual Meetings	4-14
	E. ISS Position on Virtual Shareholder Meetings	4-15
	F. ISS Position on Annual General Meetings (AGMs) of Stockholders of Non-U.S. Companies	4-15
	G. Virtual Annual Meetings and the Ubiquitous "Tax Man"	4-16
VI.	SEC INITIATIVES OTHER THAN THE RULES REGARDING SHAREHOLDER MEETINGS DISCUSSED ABOVE	4-17
	A. Introduction	4-17
	B. Relief from Certain Filing Requirements	4-17
	C. Disclosure Guidance from the Division of Corporation Finance	4-18

Table of Contents

D.	The Public Statement by the SEC Chairman and Director of the Division of Corporation Finance Re: Disclosure in the Face of COVID-19.....	4-19
E.	Going Private Transactions: A Possible Dell “Redo”	4-20
VII.	NEW YORK STOCK EXCHANGE’S RELAXATION OF TWO VOTING RULES.....	4-21
VIII.	CONCLUSION.....	4-21
IX.	APPENDIX A, EXCERPT FROM THE DESCRIPTION OF THE NOL PILL ADOPTED BY CHESAPEAKE ENERGY CORPORATION ON APRIL 23, 2020.....	4-22

Chapter 5 The DOJ’s and FTC’s Antitrust COVID-19 Initiatives

I.	SCOPE	5-2
II.	INTRODUCTION TO SUBSTANTIVE AND PROCEDURAL ANTITRUST LAWS	5-3
A.	Scope.....	5-3
B.	Section 1 of the Sherman Act.....	5-3
C.	Section 2 of the Sherman Act.....	5-3
D.	Section 7 of the Clayton Act.....	5-3
E.	The HSR Pre-Merger Notification Law	5-3
III.	SOME PROCEDURAL ISSUES UNDER THE ANTITRUST LAWS RESULTING FROM COVID-19	5-4
A.	Introduction.....	5-4
B.	Temporary e-Filing of HSR Report Forms	5-4
C.	Extension of “Timing Agreements”	5-5
D.	Early Termination of HSR Waiting Periods.....	5-5
E.	Expedited FTC and DOJ Procedure and Guidance for COVID-19 Public Health Efforts.....	5-5
IV.	SUBSTANTIVE COVID-19 ISSUES UNDER THE ANTITRUST LAWS	5-6
A.	Introduction.....	5-6
B.	DOJ and FTC Antitrust Merger Enforcement Under the 2010 DOJ/FTC Guidelines	5-6
1.	Introduction.....	5-6
2.	The Deal Lawyer’s “Hop, Skip, and Jump” Through the 2010 DOJ/FTC Guidelines	5-6
3.	Elaboration on the Failing Firm Defense and Its Potential Use in the COVID-19 Crisis	5-8
C.	The 2012 Ventilator Merger and Its Potential in This Crisis	5-11
D.	Competitor Collaboration	5-12
E.	Potential Collusion in Labor Markets.....	5-13
F.	Potential Price-Gouging on Personal Protective Equipment (PPE) and Other Products.....	5-13
V.	CONCLUSION.....	5-14

Chapter 6 Congress's and Treasury's Federal Income Tax Initiatives

I.	SCOPE	6-2
II.	THE EMPLOYEE RETENTION CREDIT FOR EMPLOYERS SUBJECT TO CLOSURE DUE TO COVID-19	6-4
A.	Introduction to Federal Employment and Self-Employment Taxes	6-4
B.	Introduction to the Employee Retention Credit for Employers	6-4
1.	The Basic Rule	6-4
2.	Recipients of PPP Loans Not Eligible	6-5
3.	Eligible Employer	6-5
a.	In General	6-5
b.	Appropriate Governmental Authority and Government Shut-Down Requirement	6-6
c.	Reversal of a Significant Decline in Gross Receipts	6-6
d.	Summary	6-7
4.	Qualified Wages	6-7
5.	Applicable Employment Taxes	6-8
6.	Limitation and Refundability	6-8
a.	The \$10,000 Qualified Wage Limitation	6-8
b.	Refundability of the Employee Retention Credit	6-9
7.	Special Rules for Work Opportunity Tax Credit and Other Overlaps	6-10
8.	Basic Illustration of the Employee Retention Credit	6-10
9.	Should a Business Take the Employee Retention Credit or the PPP?	6-12
10.	Will Generous Unemployment Benefits Work Against Both the Employee Retention Credit and the PPP?	6-13
III.	THE DELAY OF PAYMENT OF EMPLOYER PAYROLL TAXES AND SELF-EMPLOYMENT TAXES	6-14
A.	In General: The Employer Payroll Taxes	6-14
B.	Not Applicable If Loan Forgiveness Under the PPP	6-14
C.	Applicable Employment Taxes	6-14
D.	Payroll Tax Deferral Period	6-14
E.	Applicable Date	6-14
F.	Illustration	6-14
G.	The Self-Employed	6-15
H.	The "Story" with a Potential Employee Payroll Tax Cut	6-15
IV.	MODIFICATIONS TO THE NET OPERATING LOSS CARRYOVER PROVISION	6-15
A.	Background and Introduction	6-15
B.	Temporarily Overriding the TCAJA's No-Carryback Rule	6-16
C.	Temporarily Overriding the TCAJA's 20% Haircut Rule	6-16

Table of Contents

D.	IRS Guidance.....	6-16
E.	Carrybacks and the Section 965 Repatriation Tax	6-17
F.	Potential Carryback to a Pre-Consolidated Year of an Acquired Subsidiary.....	6-18
G.	Worthless Stock Deduction for a Subsidiary and the NOL Carryback.....	6-19
V.	MODIFICATION OF THE LIMITATION ON LOSSES FOR INDIVIDUAL TAXPAYERS	6-19
VI.	MODIFICATIONS OF THE LIMITATION ON BUSINESS INTEREST	6-20
VII.	CONCLUSION.....	6-20

Chapter 7 Cross-Border Inbound and Outbound COVID-19 Initiatives

I.	SCOPE	7-3
II.	INTRODUCTION TO CROSS-BORDER INVESTMENT AND M&A (1) DURING 2019, AND (2) DURING THE COVID-19 CRISIS IN THE FIRST PART OF 2020	7-4
A.	Introduction.....	7-4
B.	Some of the Principal Findings in the UNCTAD January 2020 Report on Cross-Border Investment (FDI) in 2019	7-5
C.	UNCTAD’s March 26, 2020 Assessment of the Impact on COVID-19 on Cross-Border Investment.....	7-6
III.	CFIUS REVIEW OF AN ACQUISITION BY A FOREIGN ACQUIRER OF A U.S. TARGET, THAT IS, U.S. INBOUND M&A	7-6
A.	Introduction to CFIUS.....	7-6
B.	Application of CFIUS, As Amended by FINSIA and FIRRMA, to M&A Transactions.....	7-7
1.	Introduction.....	7-7
2.	The Makeup of CFIUS; Introduction to Phase I and Phase II; and Summary of the Timing Rules.....	7-7
a.	The Makeup of CFIUS.....	7-7
b.	Introduction to Phase I “Reviews” and Phase II “Investigations”	7-8
c.	Introduction to the Timing Rules	7-8
3.	The Conduct of National Security Reviews and the Timing Rules	7-9
a.	In General	7-9
b.	Initiation of a Review, “Voluntary” or “Unilateral,” and the Effect	7-9
i.	General Principles	7-9
ii.	The Advantage of a Voluntary Filing	7-10
c.	Mandatory Declarations for Acquisitions of Certain TID Businesses	7-10

	d.	The Section 4565(f) Factors to Be Considered	7-11
	e.	The Timing Rules for the Review and the “Analysis” of the Director of National Intelligence (DNI)	7-11
4.		Situations Requiring a National Security Phase II “Investigation”	7-11
	a.	In General	7-11
	b.	The Timing Rule for a Phase II Investigation	7-12
	c.	Actions of CFIUS	7-12
	d.	Action by the President Within Fifteen Days	7-12
5.		Introduction to the Provisions of a Merger Agreement Addressing CFIUS Provisions	7-13
6.		Filing Fee Adopted on April 29, 2020	7-13
7.		Other Provisions	7-14
8.		Impact of COVID-19 on CFIUS	7-14
	a.	March 2020, President Trump Orders Divestiture of StayNTouch	7-14
	b.	Covington on What’s Happening with CFIUS in View of COVID-19	7-16
	c.	The “Adversarial Capital” Issue	7-17
	d.	Team Telecom	7-18
IV.		EU AND OTHER INVESTMENT RESTRICTIONS ON ACQUISITIONS BY U.S. ACQUIRERS OF FOREIGN TARGETS, THAT IS, U.S. OUTBOUND M&A	7-19
	A.	Introduction	7-19
	B.	The EC, 2019 FDI Screening Regulation	7-20
	C.	The EC, 2020 COVID-19 Investment Guidelines	7-21
	D.	UNCTAD, Investment Policy Responses to the COVID-19 Pandemic	7-22
	E.	Potential Relaxation of the “No Frustrating Action” Rule in the Takeover Code by Issuance of a Golden Share	7-23
	1.	Introduction	7-23
	2.	The EU’s General Approach to Defensive Tactics	7-23
	3.	Golden Shares	7-24
	a.	The EU’s Current Policy on Golden Shares	7-24
	b.	The Vietnamese Approach to Golden Shares, Written by Ngu Huu Truong, an SJD Student at Penn State Law and Research Assistant to Professor Thompson	7-25
V.		EU ANTITRUST (THAT IS, COMPETITION) ENFORCEMENT DURING THE COVID-19 CRISIS	7-25
	A.	Introduction	7-25
	B.	EU’s Approach to Antitrust Enforcement, Including with Respect to Mergers	7-26
	C.	The EU’s Failing Firm Defense (FFD) in Merger Enforcement	7-26

Table of Contents

D.	The EU's Enforcement Approach to Certain Coordination Efforts Taken by Competitors	7-27
E.	The EU's Approach to Price Gouging.....	7-28
VI.	RELAXATION OF EU'S STATE AID RULES	7-29
A.	Introduction.....	7-29
B.	The COVID-19 Exception to the EU's "No State Aid" Rule.....	7-29
1.	The Basic EU "No State Aid Rule".....	7-29
2.	Introduction to Some of the Exceptions to the "No State Aid" Rule	7-29
3.	Introduction to the EU's Temporary Frameworks on State Aid	7-30
4.	The Initiatives in the <i>March 19, Original Temporary Framework on State Aid</i> , Initiatives 3.1 to 3.5	7-31
5.	The Initiatives in the <i>April 3, First Amended Temporary Framework on State Aid</i> , Initiatives 3.6 to 3.10	7-31
6.	The Initiative in the <i>May 8, Second Amended Temporary Framework for State Aid</i> , "Recapitalization Measures"	7-31
a.	Introduction	7-31
b.	Eligibility.....	7-32
c.	Types of Recapitalisations.....	7-32
d.	Requirements That Must Be Satisfied by the Recipients of the State Aid, That Is, the Beneficiaries	7-33
7.	Illustration of a State Aid Grant: The Case of Air France.....	7-34
VII.	CONCLUSION.....	7-34

Chapter 8 Investment Banker's Valuation COVID-19 Initiatives

I.	SCOPE	8-4
II.	SOME VALUATION AUTHORITIES.....	8-5
A.	Valuation Authorities Generally	8-5
B.	Valuation Authorities in Connection with the COVID-19 Crisis.....	8-5
III.	SOME GENERAL OBSERVATIONS.....	8-6
A.	Volatility in the Markets.....	8-6
1.	In General.....	8-6
2.	Movements in the VIX Illustrate the Roller-Coaster Ride.....	8-7
3.	The Bill Ackman Trade That Took Advantage of the Market's Volatility	8-8
B.	The Performance of Highly Leveraged Firms in the Crisis	8-8
C.	Which Firms Are Most Likely to Be Adversely Affected by the COVID-19 Crisis?	8-9
D.	The Impact of Buybacks and Dividends on Firm Value During the COVID-19 Crisis.....	8-9
E.	Impact of Goodwill Impairments.....	8-10

IV.	BASIC PRINCIPLES UNDERLYING THE DCF TECHNIQUE	8-11
A.	Introduction.....	8-11
1.	In General.....	8-11
2.	Treatment of Non-Operating Assets and Assumed Debt, That Is, Net Debt.....	8-11
B.	The Concept of Present Value	8-11
C.	Basic Concept of Net Present Value	8-12
D.	Present Value of Multiyear Income Flows: The Discounted Cash Flow and Net Present Value Formulas	8-12
E.	The Five Basic Steps in Using DCF and NPV.....	8-13
F.	Estimating Free Cash Flows	8-14
1.	Introduction.....	8-14
2.	Estimating Cash Flows	8-14
G.	Estimating Terminal Value.....	8-15
H.	Use of the CAPM in Determining the Appropriate Equity Discount Rate	8-15
1.	Introduction.....	8-15
2.	BETA: The Measure of Market Risk	8-16
3.	The Risk-Free Rate	8-16
4.	The MRP	8-16
5.	The Use of the Capital Asset Pricing Model in Determining the Cost of Equity.....	8-17
I.	Use of the WACC in Determining the Appropriate DR	8-17
J.	Illustration of the Application of DCF, CAPM and NPV in the Acquisition by AC of Target	8-18
1.	Basic Transaction.....	8-18
a.	First Step: Computation of Target's FCFs and Terminal Value.....	8-18
b.	Second Step: Determination of Cost of Capital, That Is, the DR.....	8-19
i.	Assuming All Equity Financing and No Net Debt	8-19
ii.	Assume Partially Funded with Debt and Therefore Use of WACC	8-20
c.	Third Step: Discount the FCFs and Terminal Value.....	8-20
d.	Fourth Step: Sum the Present Values of the Free Cash Flows and Terminal Value.....	8-20
i.	Application Where Target Has No Non-Operating Assets That Are Going to Be Acquired and No Debt That Will Be Assumed.....	8-20
ii.	Application If Target Has Non-Operating Assets That Are Going to Be Acquired and Debt That Will Be Assumed.....	8-21

Table of Contents

e.	Fifth Step: Compute the Net Present Value	8-21
i.	In General	8-21
ii.	Sensitivity Analysis	8-22
V.	APPLYING DCF DURING THE COVID-19 CRISIS.....	8-22
A.	The General Impact on the DCF Analysis.....	8-22
B.	The General Impact of the Crisis on the Computation of Free Cash Flows	8-22
C.	Professor Damodaran’s Insights on the Potential Macro Economic Effect of a Lower Risk-Free Rate.....	8-23
D.	Professor Damodaran’s Observations on the Movements in the MRP During the Crisis	8-24
E.	The Duff & Phelps’s Suggestion of the Use of a “Normalized Risk-Free Rate”	8-24
F.	Professor Damodaran’s Computation of the Implied Equity Risk Premium.....	8-25
G.	Duff and Phelps Computation of the Equity Risk Premium.....	8-25
H.	A Potential Explanation of the Crisis Having Caused (1) a Large Change in Free Cash Flows, but (2) a Small Change in the DR.....	8-25
I.	Professor Damodaran’s Valuation of the S&P 500 on March 9, 2020.....	8-26
VI.	BASIC PRINCIPLES UNDERLYING THE COMPARABLE COMPANIES AND COMPARABLE TRANSACTIONS VALUATION TECHNIQUES.....	8-27
A.	Introduction.....	8-27
B.	The Mathematics Behind the Direct Comparison Approach	8-28
C.	Selecting Comparable Companies and Comparable Transactions.....	8-29
D.	Selecting the Comp Equity Value and the Value Factor, Including Total Firm Value to EBITDA	8-29
1.	In General.....	8-29
2.	Determining the Value Factor on a Trailing or Forward Basis	8-30
E.	Accounting for Control Premiums	8-30
F.	Professor Damodaran’s “Anatomy of a Multiple” Generally	8-30
G.	Professor Damodaran’s Comparison of the DCF and Multiples Techniques Generally	8-31
VII.	APPLYING COMPARABLE COMPANIES AND COMPARABLE TRANSACTIONS DURING THE COVID-19 CRISIS.....	8-32
A.	Professor Damodaran’s Impact of the Three Phases of a Financial Crisis on the Use of Multiples.....	8-32
B.	Professor Damodaran’s Observations on the Use of “Trailing” and “Forward” Estimates of the Value Factor in View of the COVID-19 Crisis.....	8-32
C.	Some Guidance on the Use of Multiples from the Authors of BVR, <i>COVID-19</i>	8-33

VIII.	BASIC OBSERVATIONS ON THE VALUATION METHODOLOGIES USED IN VALUING A COMPANY THAT IS IN FINANCIAL DISTRESS, INCLUDING BANKRUPTCY	8-34
IX.	ILLUSTRATION OF VALUATION IN A MERGER SIGNED DURING THE COVID-19 CRISIS—THE ACQUISITION BY UNITED COMMUNITY BANKS, INC. OF THREE SHORES BANCORPORATION, INC.	8-35
	A. Introduction.....	8-35
	B. Background on the Basic Terms of the Merger	8-35
	C. Risk Factors Re COVID 19	8-36
	D. Excerpts from the Discussion of the Fairness Opinion of the Investment Banker for Three Shores, Piper Sandler	8-38
	1. Background	8-38
	2. Comparable Company Analyses	8-38
	3. Analysis of Precedent Transactions [Comparable Transactions].....	8-39
	4. Net Present Value Analyses [DCF Analysis].....	8-39
X.	CONCLUSION	8-40

Chapter 9 The Deal Lawyer's Contract Drafting COVID-19 Initiatives

I.	SCOPE	9-3
II.	INTRODUCTION TO M&A AGREEMENTS	9-4
	A. Purpose	9-4
	B. Basic Types of Agreements and General Structure.....	9-4
	C. Tax Considerations in Structuring the Transaction Including Impact of the CARES Act	9-5
	D. Accounting Considerations in Structuring the Transaction	9-5
	E. Issuance of Securities in an Acquisition	9-5
	F. The Parties.....	9-6
	G. The Whereas Clauses	9-6
	H. The Structure	9-7
	I. The Merger Consideration	9-7
	1. In General.....	9-7
	2. Contingent Consideration and the COVID-19 Crisis	9-8
	3. The Fixed Exchange Ratio Used in the Morgan Stanley-E*Trade Merger Agreement	9-8
	4. Why the Fixed Exchange Ratio Used in the Morgan Stanley-E*Trade Merger Agreement Is Unlikely to Motivate Either Party to Walk Because of the COVID-19 Crisis.....	9-9
	J. The Definitions	9-10
	1. Introduction.....	9-10

Table of Contents

2.	The Definition of Company Material Adverse Effect in the Morgan Stanley–E*Trade Merger Agreement, the COVID-19 Carveout.....	9-11
a.	In General	9-11
b.	Note on the Interface of the Force Majeure Principle with the Definition of Company Material Adverse Effect in the Morgan Stanley–E*Trade Merger Agreement.....	9-13
c.	A Note on the Potential Interface of the Common Law Principles of Impossibility, Impracticability and Frustration with the Definition of Company Material Adverse Effect in the Morgan Stanley–E*Trade Merger Agreement.....	9-15
K.	Representations and Warranties.....	9-16
1.	In General.....	9-16
2.	CARES Act and Other COVID-19 Representations and Warranties.....	9-16
L.	Covenants.....	9-17
1.	In General.....	9-17
2.	Covenants Related to the CARES Act.....	9-17
M.	Conditions to Closing	9-17
1.	In General and the “Bring Down”	9-17
2.	The No MAE Condition Satisfied, Buyer Cannot Walk, <i>IBP</i> , the No-MAE Condition Not Satisfied, Buyer Can Walk, <i>Akorn</i>	9-18
N.	Post-Closing	9-20
O.	Advantages and Disadvantages of Various Types of Acquisition Agreements.....	9-20
III.	<i>KHAN V. CINEMEX</i> , A COVID-19 CASE, ACQUIRER WANTS TO WALK BECAUSE OF FRUSTRATION OF PURPOSE	9-20
A.	Basic Facts Relating to the Issue Presented Here	9-20
B.	Frustration of Purpose and Impossibility Excuses	9-21
IV.	<i>SP VS BUYER LP V. L BRANDS (VICTORIA’S SECRET)</i> , A COVID-19 CASE, ACQUIRER WALKS ON THE BASIS OF THE PREVENTION OF THE COMPANY’S ABILITY TO CLOSE CLAUSE OF THE MAC	9-23
A.	Basic Facts and Introduction to the Issue Presented Here	9-23
B.	Discussion of Clause (i) of the MAE, the Prevention of the Company’s Ability to Close Clause.....	9-23
V.	CONCLUSION.....	9-26
Appendix 9A	M&A Agreement Illustrative Timeline.....	App. 9A-1

Chapter 10 The Deal Lawyer's Bankruptcy Law COVID-19 Initiatives

I.	SCOPE	10-2
II.	INTRODUCTION TO BASIC BANKRUPTCY LAW PRINCIPLES.....	10-3
	A. Introduction.....	10-3
	B. Plan Sale by Bankrupt Target Under Section 363	10-3
	C. Reorganization by Bankrupt Target Under Chapter 11.....	10-3
	D. Liquidation of Bankrupt Target	10-4
III.	A SNAPSHOT OF THE WAVE OF BANKRUPTCIES RESULTING FROM THE COVID-19 CRISIS	10-4
IV.	POTENTIAL SALE OF ASSETS BY BANKRUPT TARGET UNDER SECTION 363 OF THE BANKRUPTCY CODE, AND AKORN'S POTENTIAL SECTION 363.....	10-5
	A. Introduction.....	10-5
	B. Potential Stalking Horse Bidder.....	10-6
	C. Sales Free and Clear of Non-Assumed Liabilities, Section 363(f).....	10-6
	D. Under Section 363(m), an Order Approving a Sale to a "Good Faith Purchaser" Is Not Subject to Reversal on Appeal.....	10-6
	E. <i>Akorn</i> Bankruptcy	10-7
V.	ILLUSTRATION OF A BANKRUPTCY SECTION 363 SALE OR REORGANIZATION COMBINED WITH A G REORGANIZATION UNDER SECTION 368(G) OF THE INTERNAL REVENUE CODE—AKORN'S POTENTIAL G REORGANIZATION	10-8
	A. Introduction.....	10-8
	B. <i>Akorn's</i> Potential G Reorganization	10-8
VI.	ILLUSTRATION OF A BANKRUPTCY LIQUIDATION UNDER CHAPTER 7 CAUSED BY COVID-19, ART VAN FURNITURE.....	10-9
	A. Introduction.....	10-9
	B. <i>Art Van Furniture</i> Bankruptcy	10-9
VII.	CARES ACT AMENDMENTS TO THE BANKRUPTCY CODE.....	10-10
	A. Introduction.....	10-10
	B. Temporary Modification of the Monetary Limit for Qualifying to Use the Small Business Reorganization Act.....	10-10
	C. Modification of a Plan After Confirmation As a Result of COVID-19.....	10-11
VIII.	CONCLUSION.....	10-11